RecruitingPhase 1NCT07086521
Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
Studying Facioscapulohumeral dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Restem, LLC.
- Principal Investigator
- John W Day, MD, PhDStanford University, School of Medicine, Neuromuscular Research Division
- Intervention
- ULSC(biological)
- Enrollment
- 16 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- Stanford Neuroscience Health Center, Palo Alto, California, United States
Collaborators
Solve FSHD
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07086521 on ClinicalTrials.govOther trials for Facioscapulohumeral dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07038200A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDAvidity Biosciences, Inc.
- RECRUITINGPHASE1, PHASE2NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyEpicrispr Biotechnologies, Inc.
- ENROLLING BY INVITATIONNCT07164937Imaging and Gait Analysis in FSHD PatientsFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06911190Ten Year Follow-up in FSHD: the FOCUS 3 StudyRadboud University Medical Center
- RECRUITINGNCT07409142BetterLife FSHD: A Patient-driven Health and Research PlatformFSHD Society
- ENROLLING BY INVITATIONPHASE2NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity Biosciences, Inc.
- RECRUITINGNANCT06600308Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular DystrophiesCentre Hospitalier Universitaire Dijon
- ACTIVE NOT RECRUITINGPHASE2NCT06222827Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1Centre Hospitalier Universitaire de Nice